Patient
|
Age
|
Diagnosisa
|
Donorb
|
Source of graftc
|
Conditioning regimend
|
aGvHDe stage
|
Onset of aGvHD (days)
|
Relapse (days)
|
Last follow up (days)
|
Status at last follow up
|
Cause of death
|
---|
149
|
32
|
AML
|
U
|
PB
|
MAC
|
No
|
-
|
69
|
156
|
Dead
|
Relapse/Progression
|
150
|
26
|
DLBCL
|
R
|
PB
|
RIC
|
I
|
38
|
no
|
149
|
Dead
|
Infection
|
151
|
49
|
AML
|
R
|
PB
|
MAC
|
IV
|
12
|
124
|
293
|
Dead
|
Fungal Infection - Rejection/Poor graft Functionf
|
152
|
33
|
B-ALLg
|
U
|
PB
|
MAC
|
III
|
88
|
no
|
137
|
Dead
|
Infection
|
153
|
37
|
SAA
|
R
|
PB + BM
|
MAC
|
II
|
40
|
no
|
307
|
Dead
|
Unknown
|
154
|
46
|
AMLh
|
R
|
PB
|
MAC
|
No
|
-
|
299
|
365
|
Dead
|
Haemorrhage - CNS Toxicity
|
155
|
42
|
MM
|
R
|
PB
|
MAC
|
No
|
-
|
151
|
485
|
Dead
|
Relapse/Progression
|
-
aAML, acute myeloid leukemia; DLBCL, Diffuse Large B cell Lymphoma; B-ALL, B-cell Acute Lymphoid Leukemia; SAA, Severe Aplastic Anemia; MM, Multiple Myeloma
-
bMatched related (R) and matched unrelated (U) donor
-
cPB, peripheral blood; BM, bone marrow
-
dMAC, MyeloAblative Conditioning regimen; RIC, Reduced Intensity Conditioning
-
eaGvHD, acute Graft versus Host Disease
-
fremission induced by chemotherapy upon relapse (day 124)
-
gPatient previously diagnosed (year 1991) with CML t(9;22)
-
hSubclass III, according to the French American British classification of AML